Bristol-Myers Squibb (BMY) Announces Two- and Three-Year Survival Data for Nivolumab
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced updated survival data from the advanced melanoma cohort (n=107) of the expanded Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
